• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在之前多次无并发症的疗程后出现对卡铂的过敏反应。

Anaphylaxis to carboplatin following multiple previous uncomplicated courses.

作者信息

Sood A K, Gelder M S, Huang S W, Morgan L S

机构信息

Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville 32610-0294, USA.

出版信息

Gynecol Oncol. 1995 Apr;57(1):131-2. doi: 10.1006/gyno.1995.1111.

DOI:10.1006/gyno.1995.1111
PMID:7705695
Abstract

Hypersensitivity reactions to carboplatin are rare but potentially life-threatening complications. A patient with an anaphylactic reaction to carboplatin is presented. This patient had received multiple courses of platinum-based chemotherapy including cisplatin and carboplatin. Close patient monitoring during chemotherapy is essential and skin testing to identify the etiologic agent is indicated when hypersensitivity reactions occur in the setting of combination chemotherapy.

摘要

对卡铂的过敏反应虽罕见,但可能是危及生命的并发症。本文介绍了一名对卡铂发生过敏反应的患者。该患者接受过包括顺铂和卡铂在内的多疗程铂类化疗。化疗期间密切监测患者至关重要,当联合化疗时发生过敏反应,需进行皮肤试验以确定病因。

相似文献

1
Anaphylaxis to carboplatin following multiple previous uncomplicated courses.在之前多次无并发症的疗程后出现对卡铂的过敏反应。
Gynecol Oncol. 1995 Apr;57(1):131-2. doi: 10.1006/gyno.1995.1111.
2
Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin.用铂盐进行皮肤试验以证明卡铂和顺铂之间不存在交叉反应的效用。
Ann Allergy Asthma Immunol. 2008 Jan;100(1):86. doi: 10.1016/S1081-1206(10)60410-3.
3
Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?在 3 例对卡铂过敏的患者中应用顺铂:皮肤试验是否有用?
Anticancer Drugs. 2010 Mar;21(3):333-8. doi: 10.1097/CAD.0b013e32833418c0.
4
Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.复发性卵巢癌患者对卡铂严重过敏反应后顺铂的安全性
Anticancer Res. 2003 Jul-Aug;23(4):3465-8.
5
Death from anaphylaxis to cisplatin: a case report.死于顺铂过敏反应:一例报告。
Gynecol Oncol. 1994 Apr;53(1):121-2. doi: 10.1006/gyno.1994.1098.
6
[Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].[3例复发性卵巢癌患者在卡铂相关过敏反应后使用顺铂成功脱敏]
Gan To Kagaku Ryoho. 2007 Sep;34(9):1505-8.
7
Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.上皮性卵巢癌和原发性腹膜癌患者在发生卡铂过敏反应后未进行脱敏处理而使用顺铂的情况。
Am J Obstet Gynecol. 2007 Aug;197(2):199.e1-4; discussion 199.e4-5. doi: 10.1016/j.ajog.2007.04.044.
8
Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
Gynecol Oncol. 2002 Mar;84(3):378-82. doi: 10.1006/gyno.2001.6519.
9
Anaphylaxis to cisplatin: diagnosis and value of pretreatment in prevention of recurrent allergic reactions.
Ann Allergy. 1994 Sep;73(3):271-2.
10
Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.扩大皮内皮肤试验经验以预测卡铂过敏反应的有无。
J Clin Oncol. 2003 Dec 15;21(24):4611-4. doi: 10.1200/JCO.2003.05.539.

引用本文的文献

1
Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report.卡铂输注继发心脏骤停后的成功复苏:一例报告
Gynecol Oncol Rep. 2017 Dec 14;23:7-9. doi: 10.1016/j.gore.2017.12.002. eCollection 2018 Feb.
2
Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy.在以铂类为基础的一线化疗结束十年后,再次使用卡铂治疗引发的超敏反应。
Case Rep Oncol. 2009 Feb 20;2(1):20-23. doi: 10.1159/000203358.
3
Hypersensitivity reactions to carboplatin in children.
儿童对卡铂的超敏反应。
J Neurooncol. 2002 May;58(1):33-7. doi: 10.1023/a:1015853200090.